JP2023524789A5 - - Google Patents
Info
- Publication number
- JP2023524789A5 JP2023524789A5 JP2022567419A JP2022567419A JP2023524789A5 JP 2023524789 A5 JP2023524789 A5 JP 2023524789A5 JP 2022567419 A JP2022567419 A JP 2022567419A JP 2022567419 A JP2022567419 A JP 2022567419A JP 2023524789 A5 JP2023524789 A5 JP 2023524789A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- pharmaceutical composition
- amino
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063021772P | 2020-05-08 | 2020-05-08 | |
| US63/021,772 | 2020-05-08 | ||
| US202063117388P | 2020-11-23 | 2020-11-23 | |
| US63/117,388 | 2020-11-23 | ||
| PCT/IB2021/053867 WO2021224867A1 (en) | 2020-05-08 | 2021-05-06 | Pharmaceutical combination comprising tno155 and nazartinib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023524789A JP2023524789A (ja) | 2023-06-13 |
| JP2023524789A5 true JP2023524789A5 (https=) | 2024-05-16 |
Family
ID=75904981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567419A Pending JP2023524789A (ja) | 2020-05-08 | 2021-05-06 | Ｔｎｏ１５５及びナザルチニブを含む医薬組合せ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230172928A1 (https=) |
| EP (1) | EP4146217A1 (https=) |
| JP (1) | JP2023524789A (https=) |
| KR (1) | KR20230008719A (https=) |
| CN (1) | CN115397421A (https=) |
| AU (1) | AU2021267213B2 (https=) |
| BR (1) | BR112022022305A2 (https=) |
| CA (1) | CA3179994A1 (https=) |
| IL (1) | IL297043A (https=) |
| MX (1) | MX2022013867A (https=) |
| TW (1) | TW202207933A (https=) |
| WO (1) | WO2021224867A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112867718B (zh) | 2018-09-29 | 2025-03-04 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物的制造 |
| IL305106B2 (en) | 2018-09-29 | 2025-08-01 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
| US12441737B2 (en) | 2020-07-08 | 2025-10-14 | Novartis Ag | Manufacture of compounds and compositions for inhibiting the activity of SHP2 |
| US20250127782A1 (en) | 2021-09-08 | 2025-04-24 | Amgen Inc. | Methods of treating cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| CA3048340A1 (en) * | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| IL305106B2 (en) * | 2018-09-29 | 2025-08-01 | Novartis Ag | Process of manufacture of a compound for inhibiting the activity of shp2 |
-
2021
- 2021-05-06 CA CA3179994A patent/CA3179994A1/en active Pending
- 2021-05-06 CN CN202180028103.7A patent/CN115397421A/zh active Pending
- 2021-05-06 BR BR112022022305A patent/BR112022022305A2/pt unknown
- 2021-05-06 IL IL297043A patent/IL297043A/en unknown
- 2021-05-06 JP JP2022567419A patent/JP2023524789A/ja active Pending
- 2021-05-06 MX MX2022013867A patent/MX2022013867A/es unknown
- 2021-05-06 US US17/997,885 patent/US20230172928A1/en active Pending
- 2021-05-06 WO PCT/IB2021/053867 patent/WO2021224867A1/en not_active Ceased
- 2021-05-06 KR KR1020227038204A patent/KR20230008719A/ko active Pending
- 2021-05-06 AU AU2021267213A patent/AU2021267213B2/en active Active
- 2021-05-06 TW TW110116377A patent/TW202207933A/zh unknown
- 2021-05-06 EP EP21725260.0A patent/EP4146217A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023524789A5 (https=) | ||
| US12343344B2 (en) | Pharmaceutical combination comprising TNO155 and ribociclib | |
| JP7579465B2 (ja) | 頭頸部癌の治療のためのｅｇｆｒ阻害剤 | |
| EP2827859B1 (en) | Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders | |
| EP3515446B1 (en) | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor | |
| JP2022519375A5 (https=) | ||
| EP3442529B1 (en) | Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer | |
| AU2016256471A1 (en) | Methods of treating cancer | |
| JP2017529382A5 (https=) | ||
| AU2021267213B2 (en) | Pharmaceutical combination comprising TNO155 and nazartinib | |
| CN1511036B (zh) | 包含信号转导抑制剂和埃坡霉素衍生物的联合形式 | |
| EP4106756A1 (en) | Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc | |
| CN104039148A (zh) | 组合als疗法 | |
| JP2021522246A (ja) | 癌治療のための併用 | |
| CN116171159A (zh) | 使用突变idh1抑制剂、脱氧腺苷类似物和铂药物的组合治疗 | |
| WO2023031798A1 (en) | Dosing regimen for a tead inhibitor | |
| CA3037456C (en) | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor | |
| CA2712087A1 (en) | Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit with imatinib | |
| AU2013201993B2 (en) | Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib | |
| HK40004472A (en) | Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer | |
| HK40004472B (en) | Combination therapy with notch and cdk4/6 inhibitors for the treatment of lung cancer | |
| MX2014000455A (es) | Terapia de combinacion para esclerosis lateral amiotrofica. |